Avalyn Pharma (NASDAQ:AVLN) Upgraded at Raymond James Financial

by · The Markets Daily

Raymond James Financial upgraded shares of Avalyn Pharma (NASDAQ:AVLN – Free Report) to a moderate buy rating in a research report sent to investors on Friday morning,Zacks reports.

Other equities analysts have also recently issued reports about the stock. Weiss Ratings assumed coverage on shares of Avalyn Pharma in a research note on Thursday, August 13th. They set a “sell (d+)” rating for the company. Wall Street Zen downgraded shares of Avalyn Pharma from a “hold” rating to a “sell” rating in a research note on Sunday, September 20th. Finally, Morgan Stanley upped their target price on Avalyn Pharma from $53.00 to $57.00 and gave the company an “overweight” rating in a research note on Thursday, August 13th. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $60.00.

Get Our Latest Stock Report on Avalyn Pharma

Avalyn Pharma Stock Performance

NASDAQ:AVLN opened at $28.13 on Friday. The stock has a market cap of $1.25 billion and a price-to-earnings ratio of -1.23. The firm’s fifty day moving average is $33.49. Avalyn Pharma has a fifty-two week low of $24.15 and a fifty-two week high of $40.17. The company has a quick ratio of 33.12, a current ratio of 33.12 and a debt-to-equity ratio of 0.04.

Avalyn Pharma (NASDAQ:AVLN – Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.98) EPS for the quarter, topping the consensus estimate of ($1.03) by $0.05. Equities analysts forecast that Avalyn Pharma will post -3.81 EPS for the current year.

Hedge Funds Weigh In On Avalyn Pharma

A number of hedge funds have recently added to or reduced their stakes in the stock. Montanova Capital LLC purchased a new position in shares of Avalyn Pharma in the 2nd quarter valued at $82,402,000. Bank of New York Mellon Corp bought a new position in shares of Avalyn Pharma in the 2nd quarter worth $1,321,000. Braidwell LP purchased a new stake in shares of Avalyn Pharma during the 2nd quarter worth $26,382,000. Finally, State Street Corp purchased a new stake in shares of Avalyn Pharma during the 2nd quarter worth $10,501,000.

About Avalyn Pharma

(Get Free Report)

Avalyn Pharma, Inc is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for serious fibrotic lung diseases. The company’s primary focus is pulmonary fibrosis, a group of progressive conditions in which scar tissue builds up in the lungs and impairs breathing.

Avalyn’s lead product candidate is AP01, an inhaled formulation of pirfenidone being developed for the treatment of idiopathic pulmonary fibrosis and other forms of pulmonary fibrosis. By delivering therapy directly to the lungs, Avalyn aims to provide a treatment option that may improve local drug exposure while potentially reducing some of the tolerability challenges associated with oral antifibrotic therapies.

The company’s development programs are centered on advancing inhaled medicines through clinical testing and, if successful, regulatory review.

See Also